Tozorakimab not checked

AstraZeneca · MEDI3506

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
4 active
16 in total · 10 in the EU
Targets
 

What this is

How it works
An antibody: a lab-made immune protein built to latch onto one target in the body.-mab: monoclonal antibodies WHO name stem
How it’s given
“Participants previously randomised in the TITANIA or PROSPERO predecessor studies will receive Tozorakimab in ROMEO according to this dose regimen”In the company’s words, NCT07566195 on ClinicalTrials.gov
Tested for
Viral Lung Infection and Acute Respiratory Failure, Chronic Obstructive Pulmonary Disease, COPD, Asthma
Main trialPhase 3
“The purpose of this study is to evaluate the effect of tozorakimab, as an add-on to SoC in patients with viral lung infection requiring supplemental oxygen, on the prevention of death or progression to IMV/ECMO.”In the company’s words, NCT05624450 on ClinicalTrials.gov
Other names
MEDI3506

Other drugs for Viral Lung Infection and Acute Respiratory Failure

All 23 drugs for Viral Lung Infection and Acute Respiratory Failure

Coming up3

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials16

TrialPhaseCompletesWhat it tests
Phase 3Recruiting 4 Nov 2027 Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen
Phase 3Recruiting 29 Dec 2028 Long-term Safety and Tolerability of Tozorakimab in Patients With COPD and History of Exacerbations
Phase 2Recruiting 7 Jun 2027 Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids
Phase 3Completed 19 Jan 2026 Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations
Phase 3Completed 19 Jan 2026 Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations.
Phase 3Completed 26 Feb 2026 Long-term Efficacy and Safety of Tozorakimab in Participants With Chronic Obstructive Pulmonary Disease With a History of Exacerbations (PROSPERO).
Phase 3Completed 6 Mar 2026 Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations
Phase 2Completed 21 Jul 2022 Efficacy and Safety of MEDI3506 in Adult Subjects With Atopic Dermatitis
Phase 2Completed 12 Dec 2022 Study to Assess the Efficacy and Safety of MEDI3506 in Adults With Uncontrolled Moderate-to-severe Asthma
Phase 2Completed 16 May 2023 A Phase 2b Diabetic Kidney Disease Study
Phase 2Completed 30 May 2023 A Phase II, Randomized, Double-blind, Placebo-controlled Study to Assess MEDI3506 in Participants With COPD and Chronic Bronchitis
Phase 2Completed 21 Apr 2026 A Study to Investigate Efficacy and Safety of Tozorakimab Injections Compared With Placebo in Adult Participants With Symptomatic Chronic Obstructive Pulmonary Disease (COPD) With a History of COPD Exacerbations and Elevated Eosinophils
Phase 1Completed 7 Feb 2022 Pharmacokinetics, Immunogenicity, Safety and Tolerability of MEDI3506 in Health Chinese Participants
Phase 1Completed 9 Sep 2024 A Study to Investigate Relative Bioavailability of Two Different Dosage Forms for Tozorakimab Via Subcutaneous Administration in Healthy Volunteers
Phase 1Completed 25 Nov 2025 An Accessorised Prefilled Syringe to an Autoinjector Pharmacokinetic Bridging Study of Tozorakimab
Phase 2Authorised not given Effects of Anti-IL33 (Tozorakimab) Upon Airway Inflammation, Remodelling and Response to Exacerbation Triggers in COPD (The MAB Trial)
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Tozorakimab

Following is part of Solo: you see every change to Tozorakimab the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in